Clinical Trial

A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

Completed
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention). This is a retrospective cohort study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for participants in the US during January 1, 2016 - December 31, 2024.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-15; most recent amendment 2026-01-21.
Status change: Enrolling by Invitation → Completed 2026-01-21
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-09-03
Trial Details
NCT Number NCT07141914
Lead Sponsor Novo Nordisk A/S
Conditions Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention
Enrollment 285,327 participants
Start Date 2025-08-29
Primary Completion 2025-12-19 (estimated)
Study Completion 2025-12-19 (estimated)
Updated on ClinicalTrials.gov 2026-01-23